LSE : 0HNC.L

BioMarin Pharmaceutical Inc.

$59.31 USD

$1.27 (2.19%)

Volume
181
Average Volume
5.97K
Market Capitalization
$10.56B
P/E Ratio
42.38
Dividend Yield
0.00%
Price Target
Year High
$99.65
Year Low
$58.89
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$5.81
Company Overview

LSE

Alexander Hardy

Biotechnology

Healthcare

0HNC.L

3221

US

USD

https://www.biomarin.com

415 506 6700

09061G101

N/A

Liquidity Metrics

0.23

5.81

4.20

2.80

0.00

Sales & Valuation

$3.22B

3.54

1.84

14.95

3.98

Profitability

$1.8

$348.9M

8.29%

11.89%

4.41%

3.13%

P/E Metrics

42.38

-0.86

-0.86

Analyst Price Target & Rating

Neutral

3/5

39 Analysts

%

Financial Health Scores

3.76

7/9

$3.81B

$8.59B

$2.38B

$473.39M

Key Metrics (TTM)

No key metrics data available.

Company Executives
Name Title
Amy Wireman Executive Vice President & Chief People Officer
Cristin Hubbard Executive Vice President & Chief Commercial Officer
Rashmi Eshwar Ramchandani VP, Chief Accounting Officer & Principal Accounting Officer
Arpit Dave Executive Vice President, Chief Digital & Information Officer
C. Greg Guyer Executive Vice President & Chief Technology Officer
Gregory Friberg Executive Vice President and Chief Research & Development Officer
Kevin Eggan Chief Scientific Officer & Senior Vice President of Research and Early Development
Alexander Hardy President, Chief Executive Officer & Director
Brian R. Mueller CFO & Executive VP of Finance
George Eric Davis Executive VP, Chief Legal Officer & Secretary
Poll Results

No votes yet today — be the first to share your view!

About BioMarin Pharmaceutical Inc. (LSE:0HNC.L) Stock

BioMarin Pharmaceutical Inc. specializes in the development and commercialization of therapeutic solutions for individuals grappling with severe and life-threatening rare diseases. Its array of market-ready products features Vimizim, an enzyme replacement therapy for mucopolysaccharidosis (MPS) IV type A; Naglazyme, a recombinant N-acetylgalactosamine 4-sulfatase addressing MPS VI; and Kuvan, a proprietary oral synthetic 6R-BH4 compound used to manage phenylketonuria (PKU), an inherited metabolic disorder. The commercial portfolio also includes Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme delivered via subcutaneous injection to lower blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for ceroid lipofuscinosis type 2 (a form of Batten dis ... ease); Voxzogo, a daily injectable c-type natriuretic peptide analog for achondroplasia; and Aldurazyme, a purified protein mirroring the natural human enzyme alpha-L-iduronidase. The company further maintains a robust pipeline of investigational treatments. This includes valoctocogene roxaparvovec, an adeno-associated virus vector currently in Phase III clinical trials for severe hemophilia A; BMN 307, an AAV5-mediated gene therapy undergoing Phase 1/2 studies aimed at normalizing blood Phe levels in PKU patients; and BMN 255, which is in Phase 1/2 development for primary hyperoxaluria. BioMarin distributes its offerings to a diverse clientele, including specialty pharmacies, hospitals, non-U.S. government entities, distributors, and pharmaceutical wholesalers across the United States, Europe, Latin America, and other international territories. Strategic alliances for licensing and collaboration exist with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. BioMarin Pharmaceutical Inc. was established in 1996 and is based in San Rafael, California.

Frequently Asked Questions

What is the current BioMarin Pharmaceutical Inc. (0HNC.L) stock price?

BioMarin Pharmaceutical Inc.(LSE:0HNC.L) stock price is $59.31 in the last trading session. During the trading session, 0HNC.L stock reached the peak price of $99.65 while $58.89 was the lowest point it dropped to. The percentage change in 0HNC.L stock occurred in the recent session was 2.19% while the dollar amount for the price change in 0HNC.L stock was $1.27.

0HNC.L's industry and sector of operation?

The LSE listed 0HNC.L is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of 0HNC.L?

Amy Wireman | Executive Vice President & Chief People Officer
Cristin Hubbard | Executive Vice President & Chief Commercial Officer
Rashmi Eshwar Ramchandani | VP, Chief Accounting Officer & Principal Accounting Officer
Arpit Dave | Executive Vice President, Chief Digital & Information Officer
C. Greg Guyer | Executive Vice President & Chief Technology Officer

How many employees does 0HNC.L have?

Number of 0HNC.L employees currently stands at 3221. 0HNC.L operates from 770 Lindaro Street, San Rafael, CA 94901, US.

Link for 0HNC.L official website?

Official Website of 0HNC.L is: https://www.biomarin.com

How do I contact 0HNC.L?

0HNC.L could be contacted at phone #415 506 6700 and can also be accessed through its website. 0HNC.L operates from 770 Lindaro Street, San Rafael, CA 94901, US.

How many shares of 0HNC.L are traded daily?

The average number of 0HNC.L shares traded daily for last 3 months was 5.97K.

What is the market cap of 0HNC.L currently?

The market value of 0HNC.L currently stands at $10.56B with its latest stock price at $59.31